Zura Bio Limited (NASDAQ:ZURA) Receives $14.33 Average Price Target from Analysts

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has earned an average recommendation of "Buy" from the eight research firms that are presently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $14.33.

A number of equities research analysts have recently commented on ZURA shares. HC Wainwright reiterated a "buy" rating on shares of Zura Bio in a research report on Thursday, April 3rd. Guggenheim reiterated a "buy" rating and set a $15.00 price objective on shares of Zura Bio in a research report on Wednesday, March 26th. Oppenheimer cut their price objective on Zura Bio from $19.00 to $17.00 and set an "outperform" rating for the company in a research report on Friday, May 9th. Finally, Chardan Capital reduced their price objective on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, March 26th.

Zura Bio Stock Up 1.8%

ZURA traded up $0.02 during trading on Wednesday, reaching $1.13. The stock had a trading volume of 536,762 shares, compared to its average volume of 440,637. The firm has a market capitalization of $77.27 million, a price-to-earnings ratio of -1.61 and a beta of -0.12. Zura Bio has a 1-year low of $0.97 and a 1-year high of $5.07. The stock has a 50 day moving average of $1.21 and a two-hundred day moving average of $1.55.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). On average, research analysts forecast that Zura Bio will post -0.65 EPS for the current fiscal year.

Institutional Trading of Zura Bio

A number of hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN grew its holdings in shares of Zura Bio by 68.6% during the fourth quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock valued at $58,000 after buying an additional 9,379 shares in the last quarter. Bank of America Corp DE boosted its position in Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company's stock worth $103,000 after acquiring an additional 9,966 shares during the period. Rhumbline Advisers boosted its position in Zura Bio by 37.3% during the 4th quarter. Rhumbline Advisers now owns 37,657 shares of the company's stock worth $94,000 after acquiring an additional 10,231 shares during the period. American Century Companies Inc. purchased a new position in Zura Bio during the 4th quarter valued at about $27,000. Finally, Prudential Financial Inc. purchased a new position in Zura Bio during the 4th quarter valued at about $28,000. Hedge funds and other institutional investors own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.